Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1115530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Luyao Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institu…. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium fortuitum, Mycobacterium chelonae, Mycobacterium Infections. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
We aimed to evaluate the activity of PBTZ169 and pretomanid against non-tuberculous mycobacteriosis (NTM) in vitro and in vivo .
Methods
The minimum inhibitory concentrations (MICs) of 11 antibiotics, against slow-growing mycobacteria (SGMs) and rapid-growing mycobacteria (RGMs) were tested using the microplate alamarBlue assay. The in vivo activities of bedaquiline, clofazimine, moxifloxacin, rifabutin, PBTZ169 and pretomanid against four common NTMs were assessed in murine models.
Results
PBTZ169 and pretomanid had MICs of >32 μg/mL against most NTM reference and clinical strains. However, PBTZ169 was bactericidal against Mycobacterium abscessus (3.33 and 1.49 log10 CFU reductions in the lungs and spleen, respectively) and Mycobacterium chelonae (2.29 and 2.24 CFU reductions in the lungs and spleen, respectively) in mice, and bacteriostatic against Mycobacterium avium and Mycobacterium fortuitum . Pretomanid dramatically decreased the CFU counts of M. abscessus (3.12 and 2.30 log10 CFU reductions in the lungs and spleen, respectively), whereas it showed moderate inhibition of M. chelonae and M. fortuitum . Bedaquiline, clofazimine, and moxifloxacin showed good activities against four NTMs in vitro and in vivo . Rifabutin did not inhibit M. avium and M. abscessus in mice.
Conclusion
PBTZ169 appears to be a candidate for treating four common NTM infections. Pretomanid was more active against M. abscessus , M. chelonae and M. fortuitum than against M. avium .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Tuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Infectious Diseases Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Zheng, L., Qi, X., Zhang, W., Wang, H., Fu, L., Wang, B., Chen, X., Chen, X., & Lu, Y. (2023). Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1115530
Vancouver
Zheng L, Qi X, Zhang W, Wang H, Fu L, Wang B, et al. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1115530
BibTeX
@article{Zheng2023,
author = {Zheng, Luyao and Qi, Xueting and Zhang, Weiyan and Wang, Hong and Fu, Lei and Wang, Bin and Chen, Xi and Chen, Xiaoyou and Lu, Yu},
title = {Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1115530}
}
EUVIMED